Brokerage Firm Rating Update on Accuray Incorporated (ARAY)

Accuray Incorporated (ARAY) : 4 analysts are covering Accuray Incorporated (ARAY) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Accuray Incorporated (ARAY) : The consensus price target for Accuray Incorporated (ARAY) is $9.75 for the short term with a standard deviation of $2.06. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $12, however, the pessimist price target for the company is $8.


Company shares have received an average consensus rating of Hold for the current week

Accuray Incorporated (NASDAQ:ARAY): The stock opened at $5.58 and touched an intraday high of $5.7 on Wednesday. During the day, the stock corrected to an intraday low of $5.53, however, the bulls stepped in and pushed the price higher to close in the green at $5.56 with a gain of 0.18% for the day. The total traded volume for the day was 663,380. The stock had closed at $5.55 in the previous trading session.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.